| Gene Symbol | OCLNPROTEIN |
| Full Name | Occludin Protein |
| Protein Family | Occludin family |
| Target Class | Structural Protein |
| Function | is an important component in the neurobiology of neurodegenerative diseases. |
| Mechanism of Action | Drugs targeting OCLN would stabilize or enhance tight junction protein interactions, reinforcing the structural integrity of the blood-brain barrier and reducing pathological barrier permeability. Therapeutic approaches would involve either direct protein stabilization or indirect modulation of occludin phosphorylation and trafficking to maintain barrier function. |
| Druggability | Low (0.32) |
| Clinical Stage | Approved |
| Molecular Weight | 65.4 kDa |
| Amino Acids | 148 aa |
| UniProt ID | Q16625 |
| GeneCards | OCLNPROTEIN |
| Human Protein Atlas | OCLNPROTEIN |
| N-terminal cytoplasmic domain | Interacts with the actin cytoskeleton |
| C-terminal cytoplasmic tail | Binds to ZO-1 and other scaffolding proteins |
| Associated Diseases | Aging, Als, Alzheimer, anxiety |
| Known Drugs/Compounds | BENVITIMOD, BYF |
| Interactions | ABCB1, ABCG2, ACHE, ACTB, Actin, Adiponectin |
| SciDEX Target | View Target Profile (10 clinical trials) |
| KG Connections | 842 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!